Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
about
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivoAdoptive immunotherapy for cancer: building on successGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenUse of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetNatural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) miceT cell receptor-like recognition of tumor in vivo by synthetic antibody fragmentEngineered T cells for cancer treatmentElimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsDesign and development of therapies using chimeric antigen receptor-expressing T cellsT cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.CAR T-cell immunotherapy: The path from the by-road to the freeway?Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.Treatment of advanced leukemia in mice with mRNA engineered T cells.Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.Tumor-associated antigens for specific immunotherapy of prostate cancerRegimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer.
P2860
Q24539093-0AB9E577-109B-4FCD-9E29-2BD45C1903E1Q24546258-3E5BEB9D-DD9A-4672-A483-71BDB910172CQ24623215-D7D62806-1E03-4C28-928B-16D5FC799A8FQ25257888-9301A762-9C1F-44B2-948D-27B598BA22F2Q26795540-15F585B3-1FAB-4307-ACFF-869893E5F2C2Q26799357-CC9ACC2C-37B3-447D-ADD4-C9B0F0634C21Q27318729-7C8E3147-7779-406C-9F15-2F85825F3DC6Q27322455-D9811EE3-CC9B-4922-A265-0DF0905167FDQ33578792-D42AC23E-5BEB-4408-AD6B-80A5942C0BA4Q33587034-5A89B77B-B23F-4869-A299-E9803DC6DFF3Q34310912-4312EF8F-06BC-4781-9ED8-86DD3BA54C33Q34520155-93A3A7FE-2887-4245-B7C9-232D38AD19A3Q35980893-AD3E5335-F467-4E7A-80A4-B29E05F47B2CQ36299662-DDBC7738-7664-40CF-8E23-AF1650E8899AQ36470354-BC7DFF13-C5CF-4A6D-9C7E-7B9F3FB820D1Q37418289-598A8007-0C1D-4079-A8E8-543844EDB7BBQ37466219-46B2A39E-278E-4732-BA48-4B9CE7EBAB62Q37751873-5A898F41-6A64-49DE-862D-7000E62BC1B8Q37861192-267A9244-F609-4D48-806A-118AEF170E72Q38632105-AF085CEA-F4AC-46A3-BB6F-3039D91622C1Q39477655-AA5E7867-4FB8-4896-B752-25D8964E1559Q39718346-C4436E7E-0788-46CC-AEA4-7FF0CDB46796Q39784230-A29FC520-0B63-4886-AA88-CDF0CAA5669EQ40165950-C5982A64-D6D2-4CE3-A614-ADB8192FA3AFQ41977894-D11911D1-45E1-47C5-96CA-82300D3F78E2Q42559059-697CAD8D-49FE-48E3-AEBB-9C62FB0C27C3Q43042018-A9000DBD-D6E5-46AE-8B28-CA7E6F2776E5
P2860
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Adoptive immunotherapy of pros ...... directed effector lymphocytes.
@en
type
label
Adoptive immunotherapy of pros ...... directed effector lymphocytes.
@en
prefLabel
Adoptive immunotherapy of pros ...... directed effector lymphocytes.
@en
P2093
P2860
P356
P1476
Adoptive immunotherapy of pros ...... directed effector lymphocytes.
@en
P2093
Alon Harmelin
Hannah Kanety
Itzhak Aizenberg
Jacob Ramon
Jehonathan H Pinthus
Keren Kaufman-Francis
Victoria Malina
Zelig Eshhar
P2860
P304
P356
10.1172/JCI22284
P407
P577
2004-12-01T00:00:00Z